Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions: Patch Testing; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Environmental Tobacco Smoke, Smoking Cessation
Interventions: nicotine replacement therapy (NRT), motivational advice, Quitline referral; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Shoulder Dislocation, Glenohumeral Dislocation, Anterior Shoulder Dislocation
Interventions: Arthroscopic Bankart repair procedure, Open Bankart, Latarjet, Post-Operative Rehabilitation; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 17 Years to 50 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Tempe, Arizona • San Diego, California • Vail, Colorado + 12 more

Conditions: Herpes Simplex Infections
Interventions: Not listed
Lead sponsor: Hologic, Inc.; Industry
Eligibility: Not listed
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 19 more

Conditions: Benign Pigmented Lesions, Facial Wrinkles
Interventions: PicoWay™ 532nm fractional handpiece, PicoWay™ 730nm wavelength, PicoWay™ 1064nm fractional handpiece; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Wayland, Massachusetts

Conditions: Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral, Tongue Neoplasms, Oropharyngeal Neoplasms, Oral Ulcer
Interventions: OncAlert; Device
Lead sponsor: Vigilant Biosciences, Inc.; Industry
Eligibility: 23 Years and older
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 26
States / cities: Beverly Hills, California • La Mesa, California • Loma Linda, California + 22 more

Conditions: Non-small Cell Lung Cancer
Interventions: CyberKnife Stereotactic Radiotherapy, Surgery; Radiation · Procedure
Lead sponsor: Accuray Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 14
States / cities: Fresno, California • Colorado Springs, Colorado • Lone Tree, Colorado + 10 more

Conditions: Sharps Injuries
Interventions: VAX-ID® 2200; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
Interventions: Placebo, Nicotine, Mecamylamine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Critical Limb Ischemia
Interventions: Serranator PTA Serration Catheter, PTA (Standard of Care); Device · Drug
Lead sponsor: Cagent Vascular LLC; Industry
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Plus, SYNERGY; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Tobacco Use in Persons Living With HIV
Interventions: Positively Smoke Free group treatment, Standard Care; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • The Bronx, New York

Conditions: Blood Pressure, Heart Disease, Hypertension (HTN), Blood Pressure Monitoring
Interventions: Model BB-613WP; Device
Lead sponsor: Biobeat Technologies Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more

Conditions: Smoking
Interventions: Mecamylamine, Nicotine Patch, Cigarette brand switching; Drug · Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions: Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Menopause, Arteriosclerosis
Interventions: Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo; Drug
Lead sponsor: Kronos Longevity Research Institute; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Osteoarthritis of the Knee
Interventions: ketoprofen Patch, Placebo Patch; Drug · Other
Lead sponsor: Hisamitsu Pharmaceutical Co., Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 36
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 31 more

Conditions: Nicotine Dependence
Interventions: Nicotine patch, ENDS, Placebo patch, Placebo ENDS; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Actinic Keratosis
Interventions: LEO 43204, LEO 43204 Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Lymphoma, Lymphoma, B-Cell
Interventions: Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq; Drug · Device
Lead sponsor: Jennifer Amengual; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Conditions: Herpes Simplex
Interventions: Vela Sentosa SA HSV1/2 Qualitative PCR Test; Device
Lead sponsor: Vela Diagnostics; Industry
Eligibility: Not listed
Enrollment: 2,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Tampa, Florida • Springfield, Massachusetts • Royal Oak, Michigan + 6 more

Conditions: Papulopustular Rosacea
Interventions: minocycline topical gel, topical gel vehicle; Drug
Lead sponsor: BioPharmX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more

Conditions: Delirium
Interventions: Clonidine, Placebo; Drug
Lead sponsor: Memorial Health University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Savannah, Georgia

Search by objective public record fields.

Evaluating for Contact Allergies in Patients With Chronic Urticaria

Nicotine Patch as an Adjunctive Intervention to Reduce Secondhand Smoke Among NICU Families

Open Versus Arthroscopic Stabilization of Shoulder Instability With Subcritical Bone Loss: The OASIS Trial

Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects

PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

A Study of VAX-ID® 2200, a New Device for Intradermal Injections

Nicotinic Modulation of the Default Network

Serrantor OCT Study

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

A Trial of Positively Smoke Free Group Therapy for HIV-infected Smokers

Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

Treatment to Quit Smoking

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Kronos Early Estrogen Prevention Study (KEEPS)

HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain

Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

Use of Transdermal Clonidine in Trauma Patients